甘李药业：博凡格鲁肽注射液还在临床中

Core Viewpoint - Ganli Pharmaceutical (603087) is currently conducting clinical trials for the injection of Bofan Glutide, and the commercial revenue generated will depend on the success and progress of subsequent research, registration, and market introduction of the product [1] Group 1 - The company is actively engaging with investors through an interactive platform [1] - The specific revenue from the product will be contingent on future developments in research and market strategies [1] - The company commits to timely information disclosure regarding important advancements in drug trials and commercialization [1]